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Abstract In critically ill children weighing <10 kg, it is
necessary to use blood as a priming solution for the
extracorporeal continuous renal replacement therapy
(CRRT) circuit before initiating CRRT to prevent hemo-
dilution and maintain adequate oxygenation. However,
blood bank blood usually contains supra-physiological
electrolyte concentrations and a non-physiological acid-
base balance that may exacerbate the patient’s condition.
The objective of this trial was to develop a simple
protocol to pre-treat blood bank-derived blood to yield a
more physiological blood priming solution. Expired
human blood in a recirculating in vitro CRRT circuit
was dialyzed prior to the initiation of CRRT using a
physiological dialysate solution. Serial blood samples
were assessed for electrolyte and pH content. Regimens
using maximal blood flow rates (180–200 ml/min) and
aggressive dialysate flow rates (33–42 ml/min) were able
to correct severely hyperkalemic and acidemic blood
within 7.5 min. Initially elevated blood potassium
concentrations >20 mEq/l were normalized to below
5 mEq/l within 7.5 min of dialysis in all cases. Blood
bank-derived blood can be “conditioned” quickly to
physiological pH and electrolyte concentrations using
these simple pre-dialysis regimens. Unlike some blood
preparation regimens that have been published, the
technique used in this trial requires no special equipment
or added medications that are not already used in CRRT.
Keywords Blood prime · Continuous renal replacement
therapy · Extracorporeal membrane oxygenation
Introduction
Newer extracorporeal therapies are being used increas-
ingly in pediatric and neonatal intensive care units to treat
critically ill children. Therapies such as continuous renal
replacement therapy (CRRT) are becoming common-
place. A difficulty with CRRT circuits used in pediatric
patients is the substantial volume (~100 ml) required to
fill the blood side of the extracorporeal circuit. In small
children weighing <10 kg, this necessitates using blood
from the blood bank as a prime in the extracorporeal
circuit because the volume in the circuit represents a
substantial fraction of the patient’s circulating blood
volume. Priming the circuit with saline or albumin does
not adequately replace the lost blood volume, which can
account for ~10% of the child’s total blood volume. In
larger patients, priming solutions such as normal saline,
lactated Ringer’s, or albumin solution can be used
successfully, but in these small patients, only the use of
blood prevents significant hemodilution when CRRT is
initiated.
The use of blood as the extracorporeal priming
solution may carry deleterious consequences. Blood
bank-derived blood may be acidemic, hyperkalemic, and
hypocalcemic. Any of these factors can lead to significant
hemodynamic instability when this blood prime is infused
into the patient at the initiation of CRRT. In addition,
these factors become increasingly important when using
the AN-69 hemofilter (Hospal, Lyon, France). When
acidemic blood comes into contact with the AN-69
membrane, patients manifest symptoms consistent with
bradykinin release [1]. Regardless of hemofilter mem-
brane type, another factor that may cause hemodynamic
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instability is the hypocalcemia caused by the citrate
anticoagulant added to blood bank blood. The anticoag-
ulant effect of citrate is due to its ability to bind free
calcium, resulting in blood that cannot form clots.
Consequently, infusion of these citrated blood primes
without adequate calcium supplementation, via infusion
or added to the dialysate, could result in severe hypocal-
cemia in small children receiving CRRT.
Strategies to pre-treat this blood prime to reduce
adverse reactions in neonatal cardiopulmonary bypass
(CPB) have been proposed [2, 3]. Journois et al. [3]
hemofiltered the blood prime prior to initiating CPB and
then replaced the removed volume with a physiological
electrolyte solution. Nagashima et al. [2] also hemofil-
tered blood prior to CPB and replaced the removed
volume with a maltose-, glucose-, and electrolyte-con-
taining solution. In both cases, the authors reported some
benefit to the technique.
Blood prime pre-treatment has not been reported for
pediatric CRRT, although alternative strategies have been
used to avoid the deleterious consequences with blood
prime infusion [1] (Table 1). In the absence of a simple
procedure, there should be careful monitoring for blood
prime infusion-related effects (especially when an AN-69
hemofilter is used). These must be treated aggressively
through the use of calcium and sodium bicarbonate
administration. The administration of these two agents
results in the formation of a precipitate, so these drugs
should be infused at different vascular access points.
Given that vascular access sites are not easily placed in
these small infants, particularly when CRRT is being
started, blood prime conditioning regimens that would
obviate these additional infusions and prevent adverse
reactions to the blood prime would be valuable.
We report the results of an in vitro blood prime
conditioning regimen that dialyzes the blood prime prior
to initiation of therapy. This regimen was performed with
two of the most commonly used CRRT machines and may
provide benefit to critically ill neonates and small
children requiring CRRT. This technique does not use
hemofiltration and requires no special equipment or added
medications not already used in CRRT. The purpose of
this study was to determine the efficacy of a CRRT blood-
conditioning regimen for use prior to initiation of CRRT
in children.
Materials and methods
An in vitro CRRT circuit set in the continuous venovenous
hemodialysis mode using blood bank-derived blood was used.
Blood was continually re-circulated while the dialysate flowed in a
non-recirculation (single-pass) mode in a countercurrent direction.
Blood priming regimens were developed for two of the most
commonly used CRRT machines on the market, the Diapact CRRT
machine (B. Braun Medical, Bethlehem, Pa., USA) and the Prisma
CRRT machine (Gambro USA, Lakewood, Colo., USA).
Dialysate
The dialysate used in all experiments was the same solution as is
used for pediatric continuous venovenous hemodialysis (CVVHD)
at our institution. This custom-made dialysate solution contained
sodium chloride 105 mEq/l, sodium bicarbonate 35 mEq/l, sodium
phosphate 1.5 mmol/l, magnesium sulfate 0.75 mEq/l, and potas-
sium chloride 3 mEq/l. Dialysate was used during priming on the
dialysate side for both experiments.
Diapact priming experiments
Diapact blood priming regimen
The Diapact CRRT machine (B.Braun Medical) was programmed
for CVVHD mode. The hemodiafilter used for each of the four
experiments was a new, non-reused Multiflow-60 hemodiafilter
(Hospal, Lyon, France) and the tubing was a standard Diapact
CRRT tubing kit (B.Braun Medical). The blood side volume of the
tubing and hemofilter was 105 ml. The arterial side of the
extracorporeal circuit was primed with 0.9% sodium chloride
containing heparin 5 units/ml according to the manufacturer’s
protocol. Using heparinized saline on the blood side and the custom
dialysate on the dialysate side, the Diapact ran its internal priming
regimen.
Diapact blood preparation
Expired unfiltered human packed red blood cells (PRBCs) were
obtained from the hospital blood bank and were diluted with 0.9%
normal saline to a hematocrit of approximately 40%. The diluted
Table 1 Blood prime conditioning approaches (CRRT continuous renal replacement therapy)
Resuscitation Blood prime bypass [3] Extracorporeal techniques
Technique THAM and calcium
added to blood
prime [7]
Saline used as prime and
discarded, replacement
blood infused post filter

















No No Dependent on ultrafiltrate replacement
solution content
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blood was transferred to an empty plastic intravenous bag (Abbott,
Chicago, Ill., USA) and warmed in a water bath to 37C.
When the machine’s priming regimen was completed, blood
replaced the saline in the circuit using the following technique. The
bag of blood was spiked with a dispensing spike (B.Braun), and a
three-way stopcock (Medex, Hilliard, Ohio, USA) was attached to
the spike (B. Braun Medical) via a Luer-lock connection. The
arterial arm of the extracorporeal circuit was attached to one of the
stopcock ports. The stopcock was opened so that blood could flow
into the arterial line. The blood pump was started and as blood was
pumped through the circuit the blood-side saline collected in the
venous waste bag. This was continued until blood reached the end
of the venous limb of the circuit. At this point the pumps were
stopped; the venous line was clamped and was detached from the
waste bag and connected to the remaining stopcock port. The
stopcock was then turned so that the remaining blood in the bag
was blocked and the venous blood flowed through the stopcock
back into the arterial arm of the circuit. At this point, the venous
line was unclamped and the blood pumps were restarted in a
recirculating manner without any dialysate flow (bypass mode).
Blood was re-circulated for approximately 5 min and then the
machine was placed into CVVHD therapy mode. Once all pumps
were running at the desired speed, the experiment was initiated.
The dialysis parameters for the experiment were blood (Qb) and
dialysate (Qd) flows of 200 ml/min and 33.3 ml/min (2 l/h),
respectively. No ultrafiltrate was formed. These are not the flow
rates that typically would be used in a small child, but were chosen
because they could be achieved with this machine and would
minimize the time necessary to condition the blood before CVVHD
initiation in a small child. The Qb and Qd capacity of the Diapact
can actually go much faster than this but are actually higher than
what is usually used clinically in our institution. We chose the
experimental flow rates similar to those we use in adult patients in
our institution.
Prisma priming experiments
Prisma blood priming regimen
The Prisma (Gambro USA) was programmed for CVVHD mode.
Two experiments were conducted with the Prisma system. The
hemodiafilter used for each of the two experiments was a new, non-
reused Multiflow-60 hemodiafilter (Hospal) and the tubing was a
standard Prisma CRRT tubing kit (Gambro USA). The blood side
volume of the tubing and hemofilter is 98 ml. The arterial side of
the extracorporeal circuit was primed with 0.9% sodium chloride
containing heparin 5 units/ml according to the manufacturer’s
protocol. Using heparinized saline on the blood side and the custom
dialysate on the dialysate side, the Prisma ran its internal priming
regimen.
Prisma blood preparation
Expired unfiltered human whole blood (hematocrit 40%) from the
University of Michigan Blood Bank was used in both Prisma trials.
Once the internal Prisma priming procedures were completed, the
whole blood was pumped into the arterial arm of the Prisma
extracorporeal circuit, as described for the Diapact circuit methods.
The dialysis parameters for the experiment were blood (Qb) and
dialysate (Qd) flows of 180 ml/min and 41.67 ml/min (2.5 l/h),
respectively. No ultrafiltrate was formed. These are not the flow
rates that would be used in a small child, but were chosen because
they were the maximum flow rates that could be achieved with this
machine and would minimize the time necessary to condition the
blood before CVVHD initiation in a small child.
Sampling strategy
The same sampling regimen was used in both the Prisma and
Diapact experiments. A 1.5-ml sample of blood was taken
immediately before any experiment was started. Once the hemo-
dialysis had begun, 1.5-ml blood samples were taken from the
arterial, venous, and effluent ports, at 2.5, 5, 7.5, 10, 15, 20, and
30 min. Samples were transferred to SST Vacutainers (Becton-
Dickson, Franklin Lakes, N.J., USA), and centrifuged at 2,000 rpm
for 30 min. The plasma was transferred to Cryovials (Fisher
Scientific, Pittsburgh, Pa., USA) and frozen at 80 C until
analyzed.
Electrolyte and pH analysis
Serum samples were analyzed via an indirect ion-selective
electrode (ISE) using an Integra 400 Plus chemical analyzer
(Roche, Indianapolis, Ind., USA). The coefficient of variance was
<1.5% for all electrolytes analyzed. All samples were run in
duplicate. The pH of the blood (pH meter, Corning 430, Fisher
Scientific) was assessed immediately before starting each experi-
ment (time zero) and again after 30 min of dialysis.
Calculations
Electrolyte clearance was calculated as: K=(E/P)Qe where
K=solute clearance, E=solute concentration in the effluent, P=sol-
ute concentration of the blood, and Qe=flow rate of the effluent
(spent dialysate).
Electrolyte clearance (K) was assessed at each sampling time.
Results of the clearance data are expressed as the mean€SD value
of each of these calculated values.
Pharmacokinetic calculation
Determination of the time it took for the concentration of the solute
in the blood to decline halfway from the recirculating blood prime
concentration to the concentration of the fresh dialysate flowing in
a single pass mode was calculated as: time for blood concentration
to get to 1/2 the difference between the blood prime and the
dialysate =0.693 (volume of the extracorporeal circuit blood
volume)/dialysate flow rate.
The application of this equation in humans is inappropriate
because a drug’s clearance and distribution volume are independent
and a perturbation of one often causes a change in half life without
changing the other parameter [4]. However, for the purposes of this
closed system with a fixed volume and clearance that is set by a
fixed pump rate, this equation works well and is appropriate.
Results
Initial blood electrolyte concentrations and pH were not
physiological. For example, initial blood potassium in
these samples, prepared from expired PRBC ranged from
9.6 to 21.3 mEq/l in the Diapact experiments and from
24.1 to 25.8 mEq/l in the Prisma experiments. Initial
sodium and chloride values were also higher than normal
blood values. Mean blood pH at baseline was 6.50 in the
Diapact and 6.35 in the Prisma experiments. At the end of
the 30-min experiment the blood pH was 7.40 for all
experiments. Serial electrolyte values were obtained and
appear in Figs. 1 and 2.
At the Qb and Qd used in these experiments, elec-
trolytes were within normal physiological concentrations
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within 5–7.5 min. This was true even in situations where
the initial potassium concentrations were as much as
fivefold above “normal” concentrations. Electrolyte
clearance approximated Qd in these experiments. In the
Diapact experiments with a Qd of 33.3 ml/min, the
mean€SD potassium clearance, sodium clearances, and
chloride clearances were 30.9€2.8, 33.4€0.1, and
33.3€0.2 ml/min, respectively. The mean€SD clearances
in the Prisma experiments with a Qd of 41.7 ml/min for
potassium, sodium, and chloride were 36.41€4.0, 39.1€
4.3, and 42.8€5.2 ml/min, respectively.
Discussion
The electrolyte clearance approximated Qd in all exper-
iments. The Qb and Qd used in the Prisma experiment were
the maximum achievable with this system. The flow rates
used in the Diapact arm of the trial were similar to rates
used in treating adults, but much higher Qb (500 ml/min)
and Qd (200 ml/min) can be achieved with this machine.
Consequently, it may be that blood conditioning can be
achieved with the Diapact even faster than we accom-
plished.
Prior to the study, we mathematically modeled the
flow rates in these experiments to provide an estimate of
the time required to modify the electrolyte content of the
blood to that of the dialysate. We developed a non-
traditional use of “half-life” to visualize the data.
Typically, the half-life of a compound is the time that is
required to reduce the compound’s concentration halfway
to zero. In this experiment, the compounds of interest
would not continually approach zero like typical first-
order drug elimination or radioactive decay. Instead, the
concentration of the compound in the blood would
continually approach the concentration of the compound
in the dialysate. This assumption is true as long as the
supply of dialysate is unlimited, the blood volume is
fixed, and the compound is not being generated within the
blood. In the present experiment, which used a closed
Fig. 1 a Potassium concentra-
tions for the Diapact experi-
ments 1–4 over time (top
graph). b Sodium and chloride
concentrations for the Diapact
experiments 1–4 over time
(bottom graph)
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system with a fixed volume and clearance that is set by a
fixed pump rate, this equation works well. Indeed,
inserting the known blood side volume of the prime
(98 ml Prisma or 105 ml Diapact) and the Qd used in each
experiment (41.7 ml/min Prisma or 33.3 ml/min Diapact)
results in a predicted time for the blood concentration to
get to half the difference between the blood prime and the
dialysate of 1.62 or 2.19 min, respectively. Experimen-
tally, this time was nearly identical to the calculated
values. Each of these “half-lives” brings the blood solute
content 50% closer to the fresh dialysate concentrations.
Consequently, after 4 or 5 half-lives (8–10 min) the blood
electrolyte content should be nearly identical to that of
fresh dialysate.
This experiment used blood with a very high initial
potassium concentration, possibly because they were from
expired whole blood (Prisma experiments) or PRBC
(Diapact experiments). Nonetheless, Brophy et al. [1]
reported that there are high concentrations of potassium in
the blood prime when non-expired blood bank PRBCs are
used. CRRT initiation rapidly delivers a substantial
potassium bolus to these critically ill children. For
example, a non-pre-dialyzed 100-ml blood prime with a
potassium concentration of 20 mEq/l could be infused at a
rate of 10 ml/min into a 2-kg critically ill child, resulting
in 2 mEq of potassium infused within 10 min. This may
lead to cardiac instability. Pre-dialysis of the blood prime
would eliminate this potassium bolus. In countries outside
of the United States, clinicians may have the option of
using a smaller, more infant-oriented tubing system with a
smaller blood side volume. For example, the Prisma M10
Pre Set system (Gambro, Lyon, France) contains a 0.042-
m2 AN69 hemodiafilter and a PVC tubing kit with a total
blood side volume of 50 ml. This kit would require a
smaller blood prime but at the cost of having to use a
hemofilter with a surface area that is substantially smaller
than we used in our study (0.6 m2).
The anticoagulant used in whole blood and PRBC is
citrate, which binds to free calcium and prevents clotting.
Consequently, the infusion of these blood primes delivers
Fig. 2 a Potassium concentra-
tions for the Prisma experi-
ments 1 and 2 over time (top
graph). b Sodium and chloride
concentrations for the Prisma
experiments 1 and 2 over time
(bottom graph)
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unbound citrate and almost no free calcium. The unbound
citrate will bind calcium within the patient’s blood once
infused. Typically, either a separate calcium infusion or
calcium-containing dialysate is necessary to counter this
hypocalcemic effect in very small children. In settings
utilizing citrate anticoagulation, a calcium-free dialysate
is commonly used. A possible salutary effect of the blood
conditioning technique presented here is that citrate is
likely removed from the blood via dialysis because free
citrate and calcium citrate have a very small molecular
weight. Pediatric studies have documented that citrate is
easily removed by CRRT [5]. However, the calcium
content of pre-dialyzed blood as used in this experiment
would not provide calcium either because the citrate-
bound calcium is also removed by the pre-dialysis
technique. Therefore, it is imperative that a calcium
infusion be started at the initiation of CRRT to counteract
the hypocalcemic blood prime using the described
technique, unless a calcium-containing dialysate is used
in the conditioning regimen.
Bradykinin formation resulting from blood prime
contact with an AN69 hemofilter membrane is likely to
be the cause of the most serious adverse reaction
associated with CRRT in pediatric patients. Brophy et
al. [1] hypothesized that hemodynamic instability may
result from the infusion of a PRBC-based blood prime
because of the low pH of this blood. These authors
suggested that it is the addition of an acidemic blood
prime that causes an acute bradykinin release and that this
is responsible for the AN69 membrane hypersensitivity
reaction. In that report the blood prime pH was 6.1–6.4
and the 0.9% saline PRBC diluent had a pH of 5.9. In our
study, we reconstituted the PRBCs as did Brophy et al. [1]
and the pH after reconstitution was 6.5. The pH of the
expired whole blood in the present study was 6.35. Our
dialysate had a pH of 8.05, and after 30 min of the blood-
conditioning regimen the blood prime pH was 7.4 in both
the Diapact and Prisma studies. Although we used an
AN69 hemofilter in our studies, we did not directly
measure bradykinin blood concentrations. If an acidemic
blood prime is the cause for the AN69 membrane
hypersensitivity reaction, this blood-conditioning regimen
may eliminate this problem associated with CRRT
initiation. Furthermore, it is possible that this blood-
conditioning regimen could remove bradykinin directly.
The molecular weight of bradykinin (1,060 daltons) is
such that it may be removed by CVVHD. These studies
remain to be performed.
Other blood-conditioning techniques have been sug-
gested for extracorporeal therapies. Nagashima et al. [2]
reported a blood-conditioning regimen to be used prior to
CBP procedures. In this regimen, 800 ml whole blood was
circulated in the CBP circuit and then 3,300 ml of a
“hemofiltration” solution was added to the circuit. This
hemofiltration solution was then removed by hemofiltra-
tion at 250 ml/min using a highly permeable hemofilter
(HF 1.0U, Toray, Japan). This technique was documented
to reduce circuit concentrations of potassium, sodium, and
bradykinin. Once CBP was instituted, patients tended to
have better initial hemodynamics than a group that did not
have conditioned blood prior to initiation of CBP. Blood
pH values were not reported in this study. The hemofil-
tration solution in this study was not a physiological
solution and the treated blood became very hypocalcemic
and thrombocytopenic.
Others have proposed that ultrafiltration during or
immediately after cardiac bypass have had an effect on
mediators such as tumor necrosis factor (TNF), interleu-
kin-1 (IL-1), interleukin-8 (IL-8), and complement, C3a
[2, 3, 6, 7]. Journois et al. [3] found that using high-
volume, zero-balanced hemofiltration during the re-
warming period of CBP in children could reduce C3a
and TNF. In this study, two groups of patients were
randomized to either receive no hemofiltration or zero-
balanced hemofiltration using a polyacrylonitrile hemo-
filter (SA 0.6 m2, Multiflow, Hospal Laboratories,
Meyzieu, France). The volume of ultrafiltration during
the re-warming period in the hemofiltration group was
1,960 ml/m2. The patients in the hemofiltration arm also
showed significant reduction of IL-1, IL-6, IL-8, and
myelo-oxidase at 24 h. Similar results with regards to
TNF removal have been reported by Millar et al. [6]. This
study showed a significant decrease in TNF plasma
concentrations before and after hemofiltration, and con-
siderable amounts of TNF were detected in the ultrafil-
trate [6]. Convective therapies should be better at
removing inflammatory mediators than purely diffusive
therapies as in our pre-dialysis of the blood prime
technique; however, quantification of mediator clearance
in our study was not assessed.
CPB is known to be associated with numerous adverse
events that can manifest as a generalized inflammatory
response. This response involves the activation of several
inflammatory mediators. Hemofiltration seems to play a
role in reducing inflammatory mediators, but whether this
is due to convective removal or binding to the membrane,
or both, is unknown. Some studies have shown the actual
removal of mediators, and have detected TNF in the
ultrafiltrate, while other studies suggest that the recircu-
lation of the primed blood during ultrafiltration may
actually enhance the adherence of the larger inflammatory
mediators to the hemofilter. Regardless of mechanism,
patients that receive hemofiltration during or after CPB
have been shown to have lower levels of inflammatory
mediators, which ultimately may enhance patient recov-
ery.
Patients receiving extracorporeal membrane oxygen-
ation (ECMO) also receive a large blood prime and can
face similar electrolyte and acidosis issues. The Univer-
sity of Michigan ECMO team uses a blood-conditioning
regimen consisting of a buffering cocktail made with
TRIS-hydroxy-methyl aminomethane (THAM), calcium
chloride, heparin, with equal parts of PRBC and a solution
of sterile water and sodium bicarbonate. This solution
helps normalize the pH and calcium. The hematocrit is
slightly lowered. This system helps the pH; however,
hyperkalemia can still be a problem. Another approach is
using a “Bypass System” described by Brophy et al. [1].
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This technique uses stopcocks in series that allows the
saline prime to be discarded, and PRBCs, diluted 1:1 with
saline, are directly infused into the venous return catheter
port. This method minimizes the initial blood prime
exposure to the hemodiafilter, which may reduce overall
bradykinin formation. However, this method does not
change the potassium content or the pH of the PRBCs that
are directly given to the patient. If the weight of the child
is <3 kg, the PRBC mixture is markedly hyperkalemic
and acidemic, making it difficult for the child’s small
blood volume to help normalize the potassium and pH.
Furthermore, this method warrants prudence because of
the use of the citrated PRBC. A supplemental calcium
infusion should be started before connecting the patient to
the pre-dialyzed blood prime to prevent hypocalcemia
from the blood prime that has been cleared of calcium.
Although not done in our in vitro experiment, in the
clinical setting it would also be essential to filter the blood
as specified in the institution’s guidelines. In critically ill
patients receiving CRRT, there is a possibility of renal
function not recovering to a life-sustaining capacity.
Consequently, kidney transplantation might be necessary.
Filtered blood may minimize the kidney recipient’s risk
of inducing sensitization to the HLA antigens of the
donor.
In conclusion, based on the results of this experiment,
it is concluded that using this pre-dialysis method of
blood priming, blood electrolyte concentrations can be
normalized within approximately 7.5–10 min when using
a physiologically compatible dialysate solution. This
system required very little time and no extra equipment,
tubing, monitoring, or drugs to complete. This technique
worked equally well for diluted PRBCs and whole blood.
Further studies that measure inflammatory mediator
concentrations using this technique are necessary before
it is attempted in children.
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